NEW YORK, NY — October 30, 2025 — Leads & Copy — Bright Minds Biosciences, Inc. (NASDAQ: DRUG) will present at two upcoming healthcare conferences in November 2025.
Bright Minds will present at the Guggenheim 2nd Annual Healthcare Innovation Conference on November 12, 2025, at 9:00 a.m. ET. A live and archived webcast will be available on the company’s website for 60 days.
Bright Minds will also present at the Jefferies Global Healthcare Conference in London on November 10, 2025, at 12:00 p.m. GMT / 7:00 a.m. ET. There will be no webcast for this event.
Bright Minds also announced the grant of stock options to certain directors, officers, and consultants to purchase an aggregate 43,000 common shares at an exercise price of US$54.47 per share for five years. The options are subject to vesting periods.
Bright Minds Biosciences is focused on developing highly selective 5-HT2 agonists for drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders.
Contact Information:
Investor Relations
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com
Alex Vasilkevich
Chief Operating Officer
Bright Minds Biosciences Inc.
T: 414-731-6422
E: alex@brightmindsbio.com
Source: Bright Minds Biosciences, Inc.
